STAMFORD, Conn., June 20, 2025 - SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.